Metabolically activated recombinant viral vectors and methods for their preparation and use

• US 7,785,888 B2
• Filed: 09/01/2006
• Issued: 08/31/2010
• Est. Priority Date: 08/09/1999
• Status: Expired due to Fees

• Current Assignee: Genzyme Corporation (Sanofi )
• Original Assignee: Genzyme Corporation (Sanofi )
• Inventors: Carter, Barrie J.
• Primary Examiner(s): Peng; Bo
• Application Number:
  US11/514,820
• Publication Number:
  US 20070087433A1
• Time in Patent Office: 1,460 Days
• Field of Search: None
• US Class Current: 435/456
• CPC Class Codes: A61K 38/191 Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: C07K 14/70578 NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 NGF-receptor C07K14/71, TNF-receptor C07K14/7151
• CPC Class Codes: C07K 16/00 Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies antibodies with enzymatic activity, e.g. abzymes C12N9/0002
• CPC Class Codes: C07K 2319/30 Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
• CPC Class Codes: C07K 2319/33 fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2750/14143 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12P 21/06 produced by the hydrolysis of a peptide bond, e.g. hydrolysate products preparing foodstuffs by protein hydrolysis A23J3/00

Abstract

Recombinant viral vectors, especially parvovirus vectors such as adeno-associated virus (AAV) vectors, capable of enhanced expression of heterologous sequences, and methods for their construction and use, are provided. The vectors have a structure, or are capable of rapidly adopting a structure, which involves intrastrand base pairing of at least one region in a heterologous sequence.

Claims

1. A recombinant adeno-associated virus (rAAV) preparation, which rAAV virus preparation is essentially free of helper virus, comprising an rAAV particle, wherein the rAAV particle comprises an rAAV genome, wherein the rAAV genome comprises a heterologous nucleotide sequence comprising a coding region and one or more inverted terminal repeat (ITR) sequences flanking said heterologous sequence, wherein the total amount of unique sequence present in the heterologous sequence is about one-half of the heterologous sequence and wherein the heterologous sequence forms intrastrand base pairs along most or all of its length such that expression of the coding region is enhanced relative to an rAAV vector that lacks sufficient intrastrand base pairing to enhance expression.

2. An rAAV virus preparation according to claim 1, wherein the heterologous sequence encodes a protein or an RNA of therapeutic interest.

3. An rAAV virus preparation according to claim 2, wherein the heterologous sequence encodes an antisense RNA or a ribozyme.

4. An rAAV virus preparation according to claim 2, wherein the heterologous sequence is:

(i) a polynucleotide encoding a protein useful in gene therapy to relieve deficiencies caused by missing, defective or sub-optimal levels of a structural protein or enzyme;

(ii) a polynucleotide that is transcribed into an anti-sense molecule;

(iii) a polynucleotide that is transcribed into a decoy that binds a transcription or translation factor,

(iv) a polynucleotide that encodes a cellular modulator;

(v) a polynucleotide that can make a recipient cell susceptible to a specific drug;

(vi)a polynucleotide for cancer therapy;

or

(vii) a polynucleotide that encodes an antigen or antibody.

5. An rAAV virus preparation according to claim 4, wherein the heterologous sequence is the herpes virus thymidine kinase gene, an E1A tumor suppressor gene or a p53 tumor suppressor gene.

6. A composition comprising an rAAV virus preparation as defined in any one of claims 1-5 and a pharmaceutically acceptable excipient.